Peptide News
The FDA now requires every GLP-1 drug label, including Ozempic, Wegovy, Mounjaro and Zepbound, to warn of NAION, a rare eye condition that can…
Read more →Researchers compared early GLP-1 prescriptions with insulin alone in women with type 2 diabetes. One analysis raised a question about heart defects.
Read more →Surveys report peptide buying from research websites and social media, interest in prescriptions, and growing payments to gray-market sellers.
Read more →A peptide vaccine for pancreatic cancer produced a strong T-cell response in a Phase 2 trial but missed its primary endpoint for recurrence-free survival.
Read more →NSW recorded 1,180 emergency visits mentioning peptide use. What hospital cases, FDA reports and independent lab testing of gray-market peptides actually establish, and what…
Read more →A new REDEFINE 1 analysis reports an estimated 25% average weight loss among women on CagriSema, with results across menopause stages. The drug remains…
Read more →The FDA is weighing temporary enforcement discretion that could let pharmacies compound certain peptides, including BPC-157. The proposal reached the White House on Oct.…
Read more →Why are Lilly and the FDA disputing retatrutide’s amino-acid count? Learn how its classification could affect approval pathways and future competition.
Read more →Nearly half of surveyed U.S. physicians say patients have reported using non-FDA-approved peptides. What is driving the trend, what the evidence shows, and how…
Read more →An investigation into disguised Facebook listings, repeated ads under different names, questionable business identities and research-only marketing, with the red flags buyers can check.
Read more →